Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Argenx Se ADR
(NQ:
ARGX
)
516.64
-0.82 (-0.16%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Argenx Se ADR
< Previous
1
2
3
Next >
argenx Appoints Steve Krognes to Board of Directors
February 27, 2023
From
argenx SE
Via
GlobeNewswire
argenx to Present at Upcoming Investor Conferences
February 27, 2023
From
argenx SE
Via
GlobeNewswire
argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023
February 23, 2023
From
argenx SE
Via
GlobeNewswire
argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
January 27, 2023
From
argenx SE
Via
GlobeNewswire
argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
January 16, 2023
From
argenx SE
Via
GlobeNewswire
argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
January 09, 2023
From
argenx SE
Via
GlobeNewswire
argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
argenx SE
Via
GlobeNewswire
argenx Appoints Ana Cespedes to Board of Directors
December 12, 2022
From
argenx SE
Via
GlobeNewswire
argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
December 10, 2022
From
argenx SE
Via
GlobeNewswire
argenx Enters Into Agreement To Acquire Priority Review Voucher
November 30, 2022
From
argenx SE
Via
GlobeNewswire
argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
November 22, 2022
From
argenx SE
Via
GlobeNewswire
argenx to Present at Upcoming Investor Conferences
November 07, 2022
From
argenx SE
Via
GlobeNewswire
argenx Reports Third Quarter 2022 Financial Results and Provides Business Update
October 27, 2022
From
argenx SE
Via
GlobeNewswire
argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022
October 20, 2022
From
argenx SE
Via
GlobeNewswire
argenx announces Extraordinary General Meeting of Shareholders on September 8, 2022
July 28, 2022
From
argenx SE
Via
GlobeNewswire
argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update
July 28, 2022
From
argenx SE
Via
GlobeNewswire
argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting
April 01, 2022
From
argenx SE
Via
Business Wire
argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
March 22, 2022
From
argenx SE
Via
Business Wire
argenx Announces VYVGART™ Approval in Japan for the Treatment of Generalized Myasthenia Gravis
January 20, 2022
From
argenx
Via
Business Wire
argenx Highlights Strategic Priorities for 2022
January 07, 2022
From
argenx
Via
Business Wire
argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis
December 17, 2021
From
argenx SE
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.